Search results below include Worst Pills, Best Pills Newsletter Articles where your
selected drug is a primary subject of discussion.
Read this article to find out which drug treatment for attention deficit hyperactivity disorder has a greater risk of psychosis in adolescents and young adults.
Abnormal involuntary movements (movement disorders) occur as adverse events associated with many widely used medications and can cause substantial hardship for affected individuals. Find out which drugs are associated with these adverse effects.
The number of children diagnosed with attention deficit hyperactivity disorder (ADHD) and treated with drugs has increased dramatically over the past decade. Learn the steps needed for an accurate ADHD diagnosis and understand the variety of treatments available before working with your child's doctor on a plan for treatment.
Patients currently taking drugs approved for the treatment of ADHD who experience any of the cardiac or psychiatric side effects mentioned in this article are advised to seek medical attention immediately.
If you are considering treatment with a stimulant ADHD drug for yourself or your child, become familiar with the new warnings for these drugs that are presented in this article. The new warnings do not tell patients that the drugs can also cause sudden death in those using the medication properly, not just in those abusing the drugs.
You should avoid these "new" single mirror images of old drugs, not out of concern about their safety or effectiveness, but because they are the same as the old drugs. In the long run, they cause economic harm both to individuals and to the health care system because they have come on the market with extended monopoly protection. Article lists some examples.
This is the second of a two-part series on drug-induced psychiatric symptoms that began in last month’s Worst Pills, Best Pills News. The information is based on the July 8, 2002 issue of The Medical Letter on Drugs and Therapeutics. Article lists drugs and adverse effects.
Dexmethylphenidate (FOCALIN), approved by the Food and Drug Administration (FDA) in November 2001 for attention-deficit/hyperactivity disorder (ADHD), joins a growing list of Do Not Use drugs, so called because they primarily result in economic harm to both individuals and the health care system. These drugs exist solely to extend a manufacturer’s brand name monopoly position in a lucrative market but offer nothing better than the drugs they replace.